<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684905</url>
  </required_header>
  <id_info>
    <org_study_id>07-00</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>7-00</secondary_id>
    <secondary_id>7-00</secondary_id>
    <nct_id>NCT00684905</nct_id>
    <nct_alias>NCT00956995</nct_alias>
  </id_info>
  <brief_title>Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy</brief_title>
  <official_title>Phase II Interstitial Brachytherapy Combined With Androgen Deprivation Therapy for Locally Recurrent Prostate Cancer After Prior External Beam Irradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such&#xD;
      as leuprolide and bicalutamide, may lessen the amount of androgens made by the body. Implant&#xD;
      radiation therapy kills tumor cells by placing material such as radioactive iodine directly&#xD;
      into or near a tumor. Giving leuprolide and bicalutamide together with implant radiation&#xD;
      therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of giving leuprolide and&#xD;
      bicalutamide together with implant radiation therapy and to see how well it works in treating&#xD;
      patients with locally recurrent prostate cancer after external-beam radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility and patient tolerance of interstitial brachytherapy combined&#xD;
           with androgen-deprivation therapy for patients with locally recurrent prostate cancer&#xD;
           after prior external-beam irradiation.&#xD;
&#xD;
        -  Determine the toxicity of interstitial brachytherapy combined with androgen-deprivation&#xD;
           therapy in these patients.&#xD;
&#xD;
        -  Determine the tumor response to interstitial brachytherapy combined with&#xD;
           androgen-deprivation therapy in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive neoadjuvant therapy comprising leuprolide acetate intramuscularly&#xD;
      for 3 months and oral bicalutamide once daily for 30 days, beginning on the first day of&#xD;
      leuprolide acetate administration. Patients then undergo interstitial brachytherapy&#xD;
      implantation with I-125. Following brachytherapy, patients receive adjuvant leuprolide&#xD;
      acetate every 3 months for an additional 6 months.&#xD;
&#xD;
      Quality of life is assessed at baseline and at every treatment and follow-up visit.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for 2 years, every to&#xD;
      4-6 months for 3 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient tolerance</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicities</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor response</measure>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprolide acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Biopsy-proven adenocarcinoma of the prostate&#xD;
&#xD;
               -  Locally recurrent disease, defined by digital rectal examination and/or rising&#xD;
                  prostate-specific antigen (PSA)&#xD;
&#xD;
          -  No evidence of nodal or distant metastasis (i.e., N0, M0) on physical examination,&#xD;
             bone scan, or CT scan of the pelvis&#xD;
&#xD;
          -  Clinical stage T1c-T3a disease at the time of recurrence&#xD;
&#xD;
          -  PSA &lt; 10 ng/mL&#xD;
&#xD;
          -  Prostate volume by transrectal ultrasonography &lt; 60 cc&#xD;
&#xD;
          -  Received prior external beam radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  WBC ≥ 3,000/μL&#xD;
&#xD;
          -  Platelet count ≥ 90,000/μL&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2 times normal&#xD;
&#xD;
          -  AST &lt; 2 times normal&#xD;
&#xD;
          -  Normal prothrombin time and partial thromboplastin time&#xD;
&#xD;
          -  No significant obstructive urinary symptoms (AUA score ≤ 16)&#xD;
&#xD;
          -  No contraindication for general anesthesia&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior transurethral resection of the prostate&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William W. Wong, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>May 14, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2008</study_first_posted>
  <last_update_submitted>November 9, 2012</last_update_submitted>
  <last_update_submitted_qc>November 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 12, 2012</last_update_posted>
  <responsible_party>
    <name_title>William Wailing Wong, M.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

